However, CAR-T cell therapy alone against the CRC targets CEA [73], EpCAM [72], GUCY2C [48], NKG2DL [75] and PLAP [80] have also demonstrated antitumour efficacy in preclinical studies. The gene discussed is EPCAM; the disease is colorectal carcinoma.